Tumor response rate (CR + PR) as measured by RECIST criteria Up to 4 years [clinicaltrials_resource:00131815b475daab19444f5424bffa55]

Tumor response rate (CR + PR) as measured by RECIST criteria Up to 4 years [clinicaltrials_resource:00131815b475daab19444f5424bffa55]

Patients receive bevacizumab IV on day 1.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:00131815b475daab19444f5424bffa55
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors [clinicaltrials:NCT00055809]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Tumor response rate (CR + PR) as measured by RECIST criteria Up to 4 years [clinicaltrials_resource:00131815b475daab19444f5424bffa55]

Patients receive bevacizumab IV on day 1.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:00131815b475daab19444f5424bffa55
Bio2RDF identifier
00131815b475daab19444f5424bffa55
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:00131815b475daab19444f5424bffa55
measure [clinicaltrials_vocabulary:measure]
Tumor response rate (CR + PR) as measured by RECIST criteria
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive bevacizumab IV on day 1.
identifier
clinicaltrials_resource:00131815b475daab19444f5424bffa55
title
Tumor response rate (CR + PR) as measured by RECIST criteria Up to 4 years
@en
inDataset
type
label
Tumor response rate (CR + PR) ...... 31815b475daab19444f5424bffa55]
@en